Dr. Boris C. Pasche M.D. Ph.D. serves as Independent Director of the Company. He has served as a director since March 2018 and is co-founder, member and Chief Executive Officer of TheraBionic Inc, formerly TheraBionic LLC and TheraBionic GmbH, companies focused on the commercialization of its first oncology application: treatment of advanced hepatocellular carcinoma. TheraBionic GmbH received European regulatory approval for its TheraBionic P1 device in July 2018. Since 2014, Dr. Pasche has served as attending physician at Wake Forest Medical Center, director at Wake Forest Baptist Comprehensive Cancer Center and he serves as chairman and holds the Charles L. Spurr Endowed Chair in Cancer Research, Department of Cancer Biology at Wake Forest University. Dr. Pasche is currently a member of the board of The Foundation for Research on Information Technologies in Society USA, Inc. From 2013 until 2016, Dr. Pasche served as associate editor of The Journal of the American Medical Association and prior to 2013 as contributing editor. From 2008 until 2014, Dr. Pasche was director of the Division of Hematology/Oncology of the University of Alabama at Birmingham (UAB) and Professor of Medicine with tenure, and the Martha Ann and David L. May Chair in Cancer Research. Dr. Pasche was associate director for Translational Research of the UAB Comprehensive Cancer Center between 2008 and 2009 and from 2009 until 2011 was deputy director of the UAB Comprehensive Cancer Center. Dr. Pasche currently serves as an editorial board member of 4Open. Dr. Pasche received his M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden and a M.D. degree from the University of Lausanne, Switzerland. Following a postdoctoral fellowship in Dr. Joseph Loscalzo’s lab at the Brigham and Women’s Hospital, Harvard Medical School, Dr. Pasche did an internship and residency in Internal Medicine at the New York Hospital, Cornell Medical Center.
As the Independent Director of Rafael Inc, the total compensation of Boris Pasche at Rafael Inc is $60,599. There are 6 executives at Rafael Inc getting paid more, with Menachem Ash having the highest compensation of $1,489,880.
Boris Pasche is 58, he's been the Independent Director of Rafael Inc since 2018. There are 6 older and 5 younger executives at Rafael Inc. The oldest executive at Rafael Holdings Inc is Stephen Greenberg, 75, who is the Lead Independent Director.
Boris's mailing address filed with the SEC is C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK, NJ, 07102.
Over the last 7 years, insiders at Rafael Inc have traded over $423,229 worth of Rafael Inc stock and bought 3,338,367 units worth $11,056,239 . The most active insiders traders include Howard S Jonas, Mark Anthony Mc Camish, and Plus, Llc I9. On average, Rafael Inc executives and independent directors trade stock every 87 days with the average trade being worth of $1,371,943. The most recent stock trade was executed by Howard S Jonas on 5 August 2022, trading 112,561 units of RFL stock currently worth $211,615.
we are a wholly owned subsidiary of rafael holdings focused on pipeline development
Rafael Inc executives and other stock owners filed with the SEC include: